Published in Drug Week, March 9th, 2007
- Second consecutive profitable quarter on a GAAP basis, with net income of $2.9 million.
- Record revenues of $62.4 million. Sales of RISPERDAL(R) CONSTA(R) by Janssen-Cilag were $226 million.
- Strong balance sheet, with cash and total investments of $356.2 million.
- Improved financial expectations, with fiscal year 2007 non-GAAP net income expected to range from $30 to $35 million.
Key operating results for the third quarter of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.